ProPhase Labs Stock-Based Compensation Growth & History (PRPH)

ProPhase Labs's stock-based compensation was $1.9M for fiscal 2025.

View full ProPhase Labs company overview

ProPhase Labs annual stock-based compensation history

ProPhase Labs annual stock-based compensation

Fiscal yearPeriod endedStock-based compensationChangeGrowth
20252025-12-31$1.9M−$1.7M−47.97%
20242024-12-31$3.6M$102,000+2.88%
20232023-12-31$3.5M−$450,000−11.29%
20222022-12-31$4.0M$803,000+25.23%
20212021-12-31$3.2M$1.7M+118.16%
20202020-12-31$1.5M$715,000+96.10%
20192019-12-31$744,000$110,000+17.35%
20182018-12-31$634,000$556,000+712.82%
20172017-12-31$78,000$77,000+7700.00%
20162016-12-31$1,000−$134,000−99.26%
20152015-12-31$135,000−$865,000−86.50%
20142014-12-31$1.0M$731,000+271.75%
20132013-12-31$269,000$23,000+9.35%
2012 · Dec 312012-12-31$246,000$115,000+87.79%
2012 · Jul 152012-07-15$50,000
20112011-12-31$131,000−$61,000−31.77%
20102010-12-31$192,000$192,000
20092009-12-31$0

ProPhase Labs stock-based compensation trends

Over the last five fiscal years, ProPhase Labs's stock-based compensation increased from $1.5M to $1.9M, a change of $434,000. The latest reported quarter, Q2 2026, shows $375,000.

About the metric

What stock-based compensation means

Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.

Calculation and source

SEC-reported stock-based compensation

TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.

Review ProPhase Labs source filings ↗

Community posts

It’s quiet here.

No posts about PRPH yet. Start the conversation.

Write the first post